Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amneal PharmaceuticalsAMRX -1.49%55 EBITDA Margin % is 21.83% as of Jun. 2026, which is 28% above its 10-year median of 17.03. GuruFocus rates AMRX with a GF Score™ of 55/100 and a GF Value™ of $8.02 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Amneal Pharmaceuticals ranks better than 68.06% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Amneal Pharmaceuticals EBITDA Margin % Related Terms
Amneal Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Amneal Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMRX vs HIMS, KNSA, INDV: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals (AMRX) has a EBITDA Margin % of 21.83% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amneal Pharmaceuticals and its competitors. This is 28% above median its historical median of 17.03. Over the past decade, Amneal Pharmaceuticals' EBITDA Margin % has ranged from 4.71 to 29.77. According to the industry distribution chart, Amneal Pharmaceuticals ranks #306 out of 958 companies in the Drug Manufacturers industry, placing it in the top 31.9%.
Is Amneal Pharmaceuticals' EBITDA Margin % too high?
Amneal Pharmaceuticals' current EBITDA Margin % of 21.83% is 28% above median its 10-year median of 17.03. Over the past 10 years, this metric has ranged from a low of 4.71 to a high of 29.77. The Drug Manufacturers industry median EBITDA Margin % is 12.11. Amneal Pharmaceuticals' value of 21.83% is 80.3% above this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #306 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amneal Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' EBITDA Margin % compare to HIMS and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #306 out of 958 companies for EBITDA Margin %. This puts Amneal Pharmaceuticals in the upper half of its industry. The industry median EBITDA Margin % is 12.11. Amneal Pharmaceuticals' value of 21.83% is 80.3% above this benchmark. Historically, Amneal Pharmaceuticals' own EBITDA Margin % has ranged from 4.71 to 29.77 over the past decade. While the company's 10-year median is 17.03 vs. the industry median of 12.11, Amneal Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current EBITDA Margin % of 21.83% is 80.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amneal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current EBITDA Margin % is 21.83%, which is 28% above median its own 10-year median of 17.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.02, compared to a current price of $17.88 — trading 122.9% above its estimated fair value. The current EBITDA Margin % is 21.83%, which is 28% above median its 10-year median of 17.03 and 80.3% above the Drug Manufacturers industry median of 12.11. Amneal Pharmaceuticals' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current EBITDA Margin % is 21.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $17.88 is trading 122.9% above its estimated GF Value™ of $8.02.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
EBITDA Margin %: 21.83% (28% above median its 10-year median of 17.03)
GF Value™: $8.02 vs. price of $17.88 (122.9% above fair value)
Industry Position: 80.3% above the Drug Manufacturers median (#306 of 958)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
55GF Score
Get the complete analysis for AMRX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 
